Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, Sung HG, Reed JC, Andreeff M
Some experimental structures explore: 48 week research durations Periodic non-research intervals between protocols Storage & Handling Store refrigerated at 28C Protect from excessive heat and sunlight Use clean laboratory handling practices Avoid repeated contamination of the vial Important Disclaimer For Laboratory and Research Purposes Only Not intended for human consumption or therapeutic use
For individuals at moderate risk of gastrointestinal complications, combined therapy of NSAIDs with a gastroprotective agent should be considered
Immune System Disorders: Anaphylaxis, hypersensitivity reactions [see Warnings and Precautions (5.2)] Skin and Subcutaneous Tissue Disorders: Toxic epidermal necrolysis, Stevens-Johnson syndrome [see Warnings and Precautions (5.2)] Nervous System Disorders: Headache Vascular Disorders: Hypertension Gastrointestinal Disorders: Abdominal pain, nausea, vomiting General Disorders and Administration Site Conditions: Malaise PAXLOVID (nirmatrelvir co-packaged with ritonavir) is a strong inhibitor of CYP3A, and an inhibitor of CYP2D6, P-gp and OATP1B1
10.1038/mp.2015.181 Mol
US$ 25.64
US$ 22.70
US$ 24.16
US$ 24.73
US$ 28.06